Clinical trials: Auto Stem Cell Transplant
Graft Versus Host Disease, Acute
Efficacy and Safety of Auto-FMT in Preventing aGVHD
To evaluation the efficacy and safety of autologous fecal microbiota transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation.
- Trial name
- NCT04745221
- Testing
- Auto-FMT with Standard Prophylaxis, Standard Prophylaxis
- Where
- China
- Volunteers
- 105 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non-Hodgkin's Lymphoma, Plasma Cell Myeloma
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
This phase II trial studies how well stem cell transplant with or without tbo-filgrastim works in treating patients with multiple myeloma or non-Hodgkin lymphoma.
- Trial name
- NCT03317899
- Testing
- Hematopoietic Cell Transplantation, Tbo-filgrastim, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NHL, Non Hodgkin Lymphoma
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or…
- Conditions
- NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT04555811
- Testing
- FT596, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Hodgkin's Disease
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
High-dose chemotherapy followed by autologous (the patient's own) peripheral blood (circulating blood) stem cell (cells that divide to form white cells, red cells and cells that help clot) transplantation is a conventional…
- Trial name
- Rituxan+BEAM (NCT01702961)
- Testing
- Melphalan, Ara-C, VP-16
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Baylor College of Medicine
Systemic Lupus Erythematosus
Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
Systemic lupus erythematosus, also known as lupus or SLE, is a chronic, multisystem, autoimmune disease in which the body's internal system of defense attacks its own normal tissues.
- Trial name
- NCT00230035
- Testing
- Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT)
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Oral Mucositis, Lymphoma
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell…
- Conditions
- Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
- Trial name
- Capella (NCT05493800)
- Testing
- MIT-001, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Multiple Myeloma
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.
- Trial name
- NCT01453088
- Testing
- Melphalan, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
Redirected Auto T Cells for Advanced Myeloma
The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD…
- Trial name
- NCT01352286
- Testing
- Autologous Genetically modified T cells
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Extensive Stage Small Cell Lung Cancer
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
The goal of this clinical trial is to learn if hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb works to treat extensive-stage small-cell lung cancer in adults.
- Trial name
- NCT06597513
- Testing
- auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
- Volunteers
- 10 people
- Sponsor
- Zhou Chengzhi
Scleroderma, Systemic, Sclerosis
Scleroderma: Cyclophosphamide or Transplantation
SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation.
- Conditions
- Scleroderma, Systemic, Sclerosis, Autoimmune Disease
- Trial name
- SCOT (NCT00114530)
- Testing
- mHSCT, cyclophosphamide
- Where
- 17 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)